The deal includes $11 billion upfront to buy the fill-finish sites ... notably Eli Lilly, which has also faced supply issues with diabetes therapy Mounjaro and obesity drug Zepbound, based on ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly’s profit doubled in ... better-than-expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter ...

including Mounjaro (for diabetes) and Zepbound (for weight loss). Together, those two products generated $5.4 billion in sales for Eli Lilly last quarter, or 40% of the top line. Demand has been ...

Eli Lilly continues to see ... the full year jumped 32% to $45.04 billion. Lilly's growth was led by its GLP-1 drugs. For the quarter, revenue for Mounjaro soared 60% year over year to $3.5 ...

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and ... Demand for Lilly’s popular GLP-1 drugs, Mounjaro and Zepbound, remains ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025 ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli ... billion. Lilly's growth was led by its GLP-1 drugs. For the quarter, revenue for Mounjaro soared ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...